Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Suzhou Raymon Pharmaceuticals Company, Ltd.
With
WuXi Clinical
Following informed consent, patients with pterygium who meet all eligibility criteria will be randomized to an 84-day double-blinded study to measure the safety and efficacy of the study drug as compared to placebo.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must be at least 18 years old
Diagnosis of pterygium with specified characteristics
BCVA of 20/200 or better
Willingness to attend all study visits and comply with the study procedures
You may not be if
Presence of ocular disease
Double pterygium
History of ocular surgery
Presence of ocular trauma
Use of any ocular medication
Use of contact lens
Allergy to any of the components of study drug
Cannot properly administer study drug
Clinically significant systemic disease that may place the subject at risk or confound study results
Participation in an investigational study within 30 days prior to screening
Female participants who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control (WOCBP).
Clareo Health | RMP-A03 Ocular Suspension in Patients With Pterygium
